Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
FULC
FULC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FULC News
Fulcrum Therapeutics Grants Stock Options to New Employee
4d ago
Newsfilter
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Fulcrum Therapeutics Reports Phase 1b Trial Results Amid Stock Decline
Feb 24 2026
Benzinga
Fulcrum Therapeutics Reports Q4 Earnings and Cash Position
Feb 24 2026
seekingalpha
Fulcrum Therapeutics Grants Stock Options to New Employee
Feb 06 2026
Newsfilter
BMO Initiates Medline Coverage with $45 Price Target
Jan 12 2026
Benzinga
Fulcrum Grants 30,400 Stock Options to New Employees at $10.84 Exercise Price
Jan 09 2026
Globenewswire
Fulcrum Therapeutics Launches $150 Million Public Offering to Fund R&D
Dec 08 2025
Globenewswire
Fulcrum Therapeutics Shares Surge Following Encouraging Sickle Cell Study Results
Dec 08 2025
Benzinga
Monday's Top Sectors: Computer Peripherals and Pharmaceuticals
Dec 08 2025
NASDAQ.COM
Crude Oil Declines by More Than 1%; Structure Therapeutics Stock Soars
Dec 08 2025
Benzinga
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Confluent Shares Surge Nearly 32%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 08 2025
Benzinga
Fulcrum Therapeutics Stock Increases Following Encouraging Phase 1b Sickle Cell Trial Outcomes
Dec 08 2025
SeekingAlpha
Fulcrum Reports Positive 20 mg Dose Trial Results with 9.9% HbF Increase
Dec 06 2025
Globenewswire
Fulcrum Reports Significant HbF Increases in 20 mg Dose Trial Results
Dec 06 2025
Newsfilter
Show More News
